NATIONAL PBM COMMUNICATION · November 29, 2013

Recall of Certain Lots of Abbott FreeStyle® Glucose Test Strips

- Abbott Diabetes Care recalled certain lots of FreeStyle® and FreeStyle Lite® Blood Glucose Test Strips due to producing out of range
 control solution results and erroneously low blood glucose results when using FreeStyle® Blood Glucose Meters, FreeStyle Flash® Blood
 Glucose Meters, and the FreeStyle® meter built into the Omnipod® System.
- A falsely low blood glucose level may lead to an insulin dosing error that could bring about a hyperglycemic episode requiring immediate medical attention.

PRODUCT SEQUESTERING ACTIONS

Affected lot(s) include:

MATERIAL DESCRIPTION	ITEM	MANUFACTURER	LOT NUMBER	EXPIRATION	MANUFACTURER INITIAL SHIP
FREESTYLE TEST STRIP 50CT	10029511 444810	9907312050	1285007	06/30/2014	11/12/2012
FREESTYLE LITE TEST STRIP 100CT	10050025 771624	9907370827	1363015 1363109 1365921	11/30/2014 11/30/2014 12/31/2014	11/12/2012
FREESTYLE LITE TEST STRIP NFRS 50CT	10050032 771701	9907370819	1365056 1366347 1367917	11/30/2014 12/31/2014 12/31/2014	11/12/2012
FREESTYLE LITE TEST STRIP 50CT	10050035 771720	9907370822	1283345	05/31/2014	11/12/2012
FREESTYLE LITE TEST STRIP INST 50CT	10051542 799876	9907371026	1281732 1283603	05/31/2014 05/31/2014	11/12/2012
FREESTYLE STRIP DL PREPACK 4X50CT	10098735 129465	699073120502	1285007	06/30/2014	11/12/2012
FREESTYLE LITE DL STRIP PREPACK 4X50CT	10098736 129472	9907370822	1283345	05/31/2014	11/12/2012
FREESTYLE LITE STRIP PREPACK 4X100CT	10098737 129484	699073708274	1363015 1363109 1365921	11/30/2014 11/30/2014 12/31/2014	11/12/2012

Following the action due dates in Product Recall Office Log # 7592 (available at:
 http://vaww.recalls.ncps.med.va.gov/WebRecalls/Recalls.html
), sequester and then return all remaining affected product at the CMOP/facility per manufacturer's instructions. Please inform your Facility Recall Coordinator when completed.

PATIENT NOTIFICATION ACTIONS

- Determine whether the affected product(s) was dispensed to any patient(s) for home administration. Consult with diabetic clinics and diabetic educators because they are typically well aware of patients on non-contracted meters and strips. CMOP data (if available) will be provided by a CMOP representative to Pharmacy Chiefs.
- If an affected lot(s) was dispensed to a patient(s) for home administration, then:
 - Identify the patient(s).
 - o Contact patient(s) who may have received the affected product(s) for home administration by any appropriate method.
 - A sample letter can be found at:

https://vaww.cmopnational.va.gov/cmop/PBM/Other%20Documents%20and%20Resources/Recall%20Patient%20Letter%20Template.doc

- Provide patient(s) in possession of the recalled product with instructions on the following:
 - How to return the product being recalled to the pharmacy.
 - How to obtain a new supply of product.
 - When the correct product is received, patients should begin using the new product and return the recalled supply as instructed
- Providers should continue to report any adverse reactions with the use of any glucose test strip(s) or glucose meter kit(s) by entering the
 information into CPRS' Allergies/ Adverse Reactions field and/or via local reporting mechanisms. Adverse events should also be reported,
 as appropriate, to the VA ADERS program and FDA MedWatch (1-800-FDA-1088, fax 1-800-FDA-0178, online at
 https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm, or by mail).

FEEDBACK NOTIFICATION ACTIONS:

- Facility Director (or physician designee): Report completion of actions to the VISN Director.
- Facility COS and Chief Nurse Executives: Forward this document to all appropriate providers who prescribe this agent (e.g., primary care providers, endocrinology, and pharmacy staff, including contract providers, etc.). In addition, forward to the Associate Chief of Staff (ACOS) for Research and Development (R&D). Forward to other VA employees as deemed appropriate. Report completion of actions to the Facility Director.
- ACOS for R&D: Forward this document to Principal Investigators (PIs) who have authority to practice at the facility and to your respective Institutional Review Board (IRB).
- VISN Directors: Within 10 business days of issue (due 12/13/2013), communicate to PBM/VAMedSAFE that all product sequestration actions have been completed via the Feedback tool: https://vaww.cmopnational.va.gov/cmop/PBM/visn_drug_recalls_alerts/default.aspx_.